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Abstract
Background: While it is well known that psychotherapy is efficacious in the treatment of mental disorders, much
less is known about the adverse effects of psychotherapeutic interventions. The aim of this systematic review is to
examine the definition, frequency, nature, and severity of adverse effects occurring parallel to or following psychotherapeutic
treatment and to compare it against control groups.
Methods: All registered randomised controlled trials published since 2004 (publication year of harm-reporting extension of
the CONSORT statement) with adult patients fulfilling clinical criteria of defined mental disorders, which compare individual
or group psychotherapy against a control group, will be included. First, a search through international trial registers as well
as a search in literature databases (e.g. MEDLINE) and in relevant journals (e.g. Trials) for study protocols will be conducted to
identify eligible trials. In a second step, we will search for respective publications of the results of the eligible studies.
Publications will be retrieved and screened for eligibility. Two previously trained, independent raters will extract the data in
duplicate. Reporting of adverse effects will be descriptively analysed regarding frequency, heterogeneity, and
longitudinal course. We will further compare the adverse effects of psychotherapeutic interventions against
various control groups. For each categorical outcome, we will calculate relative risks (RR) together with 95%
confidence intervals. For continuous outcomes, standardised mean differences (Hedges’ g) with a 95% confidence
interval will be computed. Between-study heterogeneity will be tested with the Q statistic and quantified using I2.
Discussion: Preselecting studies with regard to randomised controlled trials might induce bias due to dropout
before the beginning of treatment or end of treatment. However, we will thoroughly assess the negative effects
of randomisation, e.g. reasons for non-randomisation, if reported. Even if delayed adverse effects might be overlooked
in randomised controlled trials, these are the only sources of causal evidence.
Systematic review registration: PROSPERO International Prospective Register of Systematic Reviews 2017:
CRD42017055507 (17 January 2017)
Keywords: Psychotherapy, Harms, Adverse effects, Adverse events, Safety, Systematic review
Background
It has been argued that any intervention with the poten-
tial of relieving mental distress also bears the risk of eli-
citing adverse effects [1]. Various attempts have been
made to define adverse effects in the course of psycho-
therapeutic treatments, whereby the following terms
have been suggested [2–4]: All adverse events occurring
parallel to or following treatment are termed unwanted
event(s). Based on the supposed causality of the adverse
events, different additional terms have been suggested,
such as adverse treatment reactions or side effects
(caused by correctly applied treatment) and malpractice
reactions (caused by incorrectly or improperly applied
treatment). Adverse events that require some form of
high-intensity treatment are referred to as severe adverse
events. Due to their seriousness, severe adverse events
should always be addressed, irrespective of causality. If
treatment does not result in positive change, patients
could show either treatment non-response (no clinically
meaningful positive change after therapy) or deterior-
ation of illness (clinically meaningful negative change
after treatment). Both non-response and deterioration
can be causally related to the treatment or not.
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Regarding psychotherapy, there are a number of potential
adverse effects which are discussed, ranging from wors-
ened or novel symptoms, such as symptom substitution
[4–8], to dependence from the therapist [9], stigmatisation
[10], relationship problems or even separation [11, 12], as
well as misuse of alcohol or drugs, deliberate self-harm,
and suicidal ideation or attempts [4].
To what extent adverse effects exist and pose a prob-
lem in psychological treatments is, however, a topic of
great debate with a long history in clinical research [4,
13]. Since “reporting harms may cause more trouble and
discredit than the fame and glory associated with suc-
cessful reporting of benefits” (p. 66) [14], such reporting
has long been neglected [15, 16]. Meanwhile, adverse
event monitoring is part of Good Clinical Practice and is
ethically required by Institutional Review Boards, also
for non-invasive interventions such as psychological in-
terventions and, more specifically, psychotherapy. While
the reporting of adverse effects in biomedical research
(e.g. pharmacotherapy) usually is based on a straightfor-
ward definition of harmful events, psychological inter-
ventions still struggle with a consensus of how to define
more subtle psychological adverse effects in collaborative
interventional settings [17–20]. Taking an encompassing
position, we will focus comprehensively on adverse ef-
fects, including non-response, deterioration, and adverse
events, perceived as negative, uncomfortable, or harmful
either by the patient, the therapist, or significant others,
which were not means of therapy [21].
At present, there is a broad and somewhat inconsistent
handling of how to define and report data on the rate
and type of adverse effects in psychotherapy trials [3]. At
least some evidence is available to estimate rates of
non-response or deterioration in patients treated with
psychotherapy. Meta-analyses on the efficacy of different
forms of psychotherapy suggest that up to 50% of the
patients do not show clinically significant change, and in
about 5–20% of patients, adverse events, including treat-
ment failure and deterioration of symptoms, emergence
of new symptoms, suicidality, occupational problems or
stigmatisation, changes in the social network or strains
in relationships, therapy dependence, or undermining of
self-efficacy, should be expected [3, 22–24].
Moreover, there are some psychological interventions
that might induce harm in a significant number of pa-
tients. A review from 2007 lists some psychological in-
terventions that are potentially harmful, such as critical
incidence stress debriefing, grief counselling for normal
bereavement, and boot camp interventions for conduct
disorder [22]. In their review of the efficacy and harm of
psychotherapy, Wampold and Imel [20] point to the ne-
cessity of randomised controlled trials (RCTs) to detect
adverse effects that are causally related to the treatment.
They conclude that findings of this type are relatively
rare and mostly apply to preventive interventions and/or
psychological interventions that would not be consid-
ered psychotherapy.
Accurate and complete safety data are indispensable
for the proper evaluation of the benefit-to-harm ratio of
interventions in a medical context [25]. In psychological
interventions, most of the existing systematic reviews
primarily focus on the efficacy or effectiveness of broad
outcomes related to psychological suffering, such as re-
duction of psychological disorders and related symp-
toms, goal attainment, enhancement of well-being, and/
or psychosocial functioning [26]. Basically, to make a
balanced decision about any intervention, it is essential
to estimate comprehensive evidence according to the
benefits as well as the adverse effects [27]. Even though
the magnitude of reporting adverse effects has increased
over time, only 27% of the reviews on the evaluation of
any type of therapeutic intervention published between
1996 and 2000 included information about safety, and
only 4% explicitly reported prescriptive safety indicators
of the intervention reviewed [28]. More recently, Meister
et al. [17] found that merely one out of nine psychother-
apy trials on persistent depressive disorder reported any
information on adverse events (whereas 39 from 42
pharmacological studies published such data).
Currently, there is no systematic review focusing on the
quantitative evaluation of adverse effects of psychother-
apy; the International Prospective Register of Systematic
Reviews (PROSPERO; https://www.crd.york.ac.uk/PROS-
PERO/; accessed 20 Nov 2017) does not indicate any on-
going review dealing with adverse effects of
psychotherapy. There may be systematic adverse effects
associated with psychotherapy. Without understanding
the nature and prevalence of adverse events, patients can-
not be informed adequately about the possible risks and
benefits of psychotherapeutic interventions prior to en-
gaging in treatment [15]. Moreover, it is a recent claim in
many psychotherapy contexts that there is a need to find a
consensus on a more systematic definition and assessment
of adverse events and outcomes [4, 17–19, 21].
The proposed systematic review and meta-analysis aims
to:
1. Record the definition of adverse events in primary
studies;
2. Assess the extent to which adverse events are
specified in psychotherapy trial protocols and
publications of psychotherapy trial results in general;
3. Systematically examine the frequency, nature, and
severity of adverse events occurring parallel to or in
the wake of psychotherapeutic treatment;
4. Descriptively contrast the positive and negative
effects of psychotherapy to guide practitioners
towards a balanced treatment decision;
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5. Compare the frequency, heterogeneity, and
longitudinal course of adverse effects of
psychotherapeutic interventions against various
control groups (untreated control groups,
treatment-as-usual control groups, unspecific
treatment control groups, pharmacotherapy or
other psychotherapy interventions, head-to-head
comparison);
6. Identify relevant moderators of the frequency of
adverse events (e.g. type of treatment, type of
mental disorder); and
7. Examine the attribution of adverse effects within
the studies (e.g. treatment vs. therapist vs. patient
effects vs. other).
By focusing on a broad research question, we will be able
to evaluate a variety of potential adverse effects and will
provide a much more comprehensive view of the problems
which appear. Our review has the potential to be used as
part of a scoping exercise to identify specific adverse events
that merit a further, more detailed look in future studies
using a more narrowly focused approach [29].
After a period of research supporting the generally posi-
tive effects of psychotherapy, it is time to take a closer
look at adverse effects, predominantly to improve the
quality of psychological treatments, both in research de-
signs and general practice [4, 17–19, 21, 27, 29]. Teaching
and educating patients and therapists about these effects
will have the potential to improve the outcome of existing
treatments, to modify existing treatments, and to improve
the choice between different treatments based upon more
precise figures which reflect adverse effects. In clinical re-
search, increased knowledge about adverse effects will
stimulate the development of specific measures for these
effects and encourage routine inclusion of these measures
into clinical studies. Given the high prevalence of mental
disorders [30–32] that are treated by psychotherapy to a
large extent [33], and the great relevance of considering
adverse effects in clinical decision-making [22], addressing
the research issues mentioned is important for both pa-
tients and clinicians.
Methods/design
Design of primary studies
We will limit the inclusion to RCTs with a published
trial protocol published since 2004 (year of publication
of the Consolidated Standards of Reporting Trials
[CONSORT] extension for harms). Randomised trials
with adequate sample size offer a unique opportunity to
assess the frequency and severity of adverse events in a
controlled and objective setting, with the most compre-
hensive and systematic accumulation of pertinent infor-
mation. Such information is essential to estimate
benefit/harm ratios in the application of medical
interventions [34, 35]. Moreover, it has been stated that
the most valid estimates of non-response and deterioration
effects can be obtained from comparisons of randomly
assigned treatment and non-treatment groups [36].
Registered study protocols are recommended as a pre-
requisite for conducting clinical studies [37]. The Declar-
ation of Helsinki states that “Every clinical trial must be
registered in a publicly accessible database before recruit-
ment of the first subject” (para 35) [38]. Furthermore, the
SPIRIT 2013 Statement provides recommendations for a
minimum set of scientific, ethical, and administrative ele-
ments that should be addressed in a clinical trial protocol
[39]. Accordingly, a study protocol should contain plans
for collecting, assessing, reporting, and managing solicited
and spontaneously reported adverse events and other un-
intended effects of trial interventions (item 22). Key con-
siderations should include the severity of the adverse
event, determination of potential causality, and whether it
represents an unexpected or anticipated event [39].
Hence, in clinical trials with a published study protocol,
the probability of systematically assessed and reported ad-
verse events might be more systematised as in studies
without a published study protocol.
Population
Inclusion criteria
We will include adult patients fulfilling clinical criteria of
the following mental disorders based upon DSM-5: mood
disorders (296, 300.4, 311, 301.13); anxiety disorders (300),
including obsessive-compulsive disorders (300.3), trauma-
and stressor-related disorders (308.3, 309.81); and person-
ality disorders (301). If DSM-III/DSM-IV or ICD-9/
ICD-10 is used in a trial for the diagnosis of the respective
disorder, the study will be included as well. Undoubtedly,
besides severe and persistent mental illness and addic-
tions, these three diagnostic subgroups represent the epi-
demiologically most relevant clinical disorders within the
psychotherapeutic health service system and psychother-
apy research [40].
Exclusion criteria
Studies with children and adolescents (mean age 18 or
younger) will be excluded. Although research of adverse
effects of psychotherapy has focused on adults until
now, there is some evidence that younger people are po-
tentially more vulnerable which goes along with a higher
prevalence of negative therapy results [16, 41]. More-
over, especially, children need specific support to express
adverse effects, and children as well as adolescents may
not be free to end treatment, both of which might nega-
tively impact the informative value of the assessments of
adverse events. Because of these potential concerns in
younger populations, we decided to exclude these spe-
cific patient populations [16].
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Intervention(s)
Eligible trials will examine the effects of individual and
group psychotherapy (as defined by the authors of the
primary studies) based upon a psychotherapeutic formal
change theory (cognitive behavioural, psychodynamic,
interpersonal, systemic, humanistic-experiential, integra-
tive) performed by a professional therapist. Telemedical
interventions (e.g. Internet-delivered psychotherapy) will
be eligible as long as all other inclusion criteria are ful-
filled, i.e. there is at least some therapist contact. Inter-
ventions systematically combining psychotherapy and
pharmacotherapy will be excluded due to possibly con-
founding intervention effects.
Comparator(s)
Control interventions will be grouped into different cat-
egories of untreated control group (wait list),
treatment-as-usual (TAU) control groups, treatment con-
trol groups (attention control/non-bona fide psychother-
apy/treatment other than psychotherapy, e.g. exercise/pill
placebo), pharmacotherapy or bona fide psychotherapy in-
terventions (head-to-head comparison).
Outcomes
According to the definitions specified above, we will in-
clude the following outcomes [2, 3]:
– Adverse event (number of participants with
treatment-emergent reactions, adverse treatment
reactions or side effects, malpractice reactions),
– Treatment non-response (number of participants
with lack of clinically meaningful [positive] change
after treatment),
– Deterioration of illness (number of participants with
clinically meaningful [negative] change after
treatment).
Moreover, we will include treatment response as well
as primary and secondary outcomes (as defined by the
authors) in order to produce a comprehensive picture of
the effects and side effects of psychotherapy. Outcomes
will be considered when measured post-treatment and at
follow-up. However, we do not want to focus on prema-
ture termination since the evidence concerning this
topic was recently summarised in systematic reviews
[42–44]. The respective definitions of non-response and
deterioration will be based on the criteria that the pri-
mary studies have used.
Search strategies
Search approaches reliably yielding all the studies that
have data on adverse effects of an intervention will re-
quire a comprehensive search that might be of low
precision [29]. Therefore, a common literature search
strategy within existing databases (“top-down” strategy)
would probably lead to an unmanageable amount of re-
cords to be screened for eligibility. Such a search strat-
egy is likely to contain most of the relevant studies, but
if only a small proportion is relevant, it is very imprecise
and resource intensive [29]. To identify relevant RCTs
more efficiently, we will use a “bottom-up” strategy. In
the first step, we will look for eligible protocols of pri-
mary studies, and in the second step, we will look for re-
spective publications of results. Therefore, common
international trial registers (e.g. clinicaltrials.gov) will be
screened for eligible studies. Additionally, a comprehen-
sive search will be performed in databases (MEDLINE,
CENTRAL, PsycInfo, Web of Science) for study protocols
of randomised controlled psychotherapy trials by using a
combination of relevant keywords (psychotherapy AND
(rct OR rando*) AND protocol), limited by date of publi-
cation (01 January 2004 to present). Moreover, we will
conduct similar searches within the databases of relevant
journals (i.e. BMC Psychiatry, BMC Psychology, BMJ
Open, Contemporary Clinical Trials, Trials) without
“protocol” as a keyword. Titles and abstracts of identified
study protocols will be independently screened by two re-
viewers. Full reports of all protocols that appear to be eli-
gible or left any uncertainty will be obtained and checked
for inclusion. Disagreements will be resolved through dis-
cussion. In case of excluding a trial, reasons will be docu-
mented. Subsequently, we will search for respective
publications of eligible studies by searching in databases
(i.e. MEDLINE, CENTRAL, PsycInfo, Web of Science) via
the title, author names, and, if possible, the trial registra-
tion number and contacting the authors of relevant study
protocols. After being retrieved, the studies will be
screened once again for eligibility by two reviewers as de-
scribed above. Records and full texts will be managed by
using Endnote X.
Data extraction
First, a coding form and an additional coding manual will
be developed. Then, the coding procedure will be tested
in a pilot phase, followed by potential modifications of the
form. The coding form will allow for the standardised de-
scription and evaluation of substantial and methodological
features possibly influencing the effect sizes of the inte-
grated studies. To assure high reliability of the coding,
two previously trained, independent raters will extract the
data in duplicate. Disagreement will be resolved via
consensus discussion or consultation with a third person
(i.e. principal investigator).
The comparison between the psychotherapeutic interven-
tion and the control group will be defined as a unit of ana-
lysis (comparison level). We will extract the following data:
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▪ General information about the research report
(e.g. authors, title, publication year, publication format,
source of funding, publication language, country of
performance);
▪ Characteristics of the patients (e.g. age, gender,
partnership, socioeconomic status, primary diagnosis,
comorbidity, additional treatments);
▪ Characteristics of intervention and therapists
(e.g. type and theoretical background of treatment,
length and frequency of the intervention, number of
therapists providing treatment);
▪ Characteristics of the control group (e.g. type of
control group, level of standardisation);
▪ Methodological features (e.g. inclusion and exclusion
criteria; recruitment-, participation- and dropout rates
for each group and reasons for dropout; prospectively
planned analyses of therapist effects; therapist effects
considered in the data analysis of outcomes and
negative effects);
▪ Characteristics of outcome variables:
– Type of outcome/adverse event;
– Characteristics of an adverse event: serious,
non-serious, intervention-related or independent
of the intervention, side effect (related to the
patient or his/her social environment), for
non-response/deterioration: type of assessment;
– Quality of information on adverse effects:
exhaustiveness, accordance of the study protocol
and report of results (i.e. pre-specified in protocol
vs. not pre-specified).
– Surveillance of adverse event: active vs. passive,
anticipated vs. unanticipated, solicited vs.
unsolicited;
– Time point of assessment/occurrence
(post, follow-up; phase of psychotherapy);
▪ Effect size related parameters (frequency of adverse
events, non-response, and deterioration; sample size)
Risk of bias will be assessed by using the Risk of Bias
tool RoB 2.0 of the Cochrane Collaboration [45]. Risk of
bias assessment will be conducted by two independent
raters, and disagreement will be resolved via consensus
discussion or consultation of a third person.
Data synthesis
First, we will descriptively assess the extent to which ad-
verse events are specified in psychotherapy trial protocols
and publications of psychotherapy trial results in general.
Second, the frequency, nature, and severity of adverse
events occurring parallel to or in the wake of psychothera-
peutic treatment will be examined. This allows us to
address new adverse effects that were previously unrecog-
nised. Adverse effects will be classified as (1) adverse
event, (2) serious adverse event, (3) non-response, and (4)
deterioration. We will also provide subgroup data for dif-
ferent mental disorders, treatment modalities, psychother-
apy orientations, and treatment settings. Third, we will
descriptively compare the positive and negative effects of
treatment. Therefore, we will calculate standardised mean
differences (Hedges’ g) as between-study effect sizes with
95% confidence interval pooled across all outcomes de-
fined as primary and secondary by the authors using a
random effects model (DerSimonian and Laird). In the
fourth step, adverse effects of psychotherapeutic interven-
tions will be compared against each control group cat-
egory (as defined above) separately. For continuous
outcomes, we will calculate standardised mean differences
(Hedges’ g) with a 95% confidence interval. For categorical
outcomes, we will calculate relative risks (RR) together
with 95% confidence intervals by dividing the risk of an
event (e.g. adverse event, non-response) in the interven-
tion group by the risk of a respective event in the control
group. Since zero cells (e.g. no adverse events in one
group) cause problems with computation of estimates and
standard errors, we will add 0.5 to each cell of the 2 × 2
table for any such study. We will calculate pooled esti-
mates using both fixed effects model (Mantel-Haenszel)
and random effects model (DerSimonian and Laird).
Sensitivity analyses will be run for studies with ad-
equate sample size only, excluding trials with less than
100 participants per group [46]. Additionally, we will
run sensitivity analyses calculating risk differences with
95% confidence intervals as a measure of absolute effect
by subtracting the risk of adverse events in the control
group from the respective risk in the intervention group.
In order to identify differential effects, subgroup ana-
lyses will be conducted. A priori, we specify the type of
treatment and kind of mental disorder as potential mod-
erators. Additionally, we will conduct exploratory mod-
erator analyses depending on the availability of data.
For analysing non-response and deterioration, the
Reliable Change Index [47] will be used as the most com-
monly reported index of change. Analyses of non-response
will be conducted using the intention-to-treat approach ac-
cording to the following principle: When data on dropouts
are carried forward and included in the evaluation using
the last observation carried forward method, they will be
included as such. When dropouts were excluded from any
assessment in the primary studies (e.g. those who never
returned for assessment after randomisation), they were
considered to be non-responders in both intervention and
control groups. Between-study heterogeneity will be tested
with the Q statistic and quantified using I2 [48]. Results of
primary study effects and summary effects will be presented
in forest plots. Publication bias will be visually assessed in
funnel plots and statistically analysed using Egger’s regres-
sion test [49]. Finally, we will evaluate the strength of the
body of evidence using the GRADE system including
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considerations of within-study risk of bias, directness of evi-
dence, heterogeneity, precision of effect estimates, and risk
of publication bias [50].
Discussion
Limitations
One of the first groundbreaking findings regarding ad-
verse effects of psychotherapy was that some therapists
produced constantly negative effects while the therapies
delivered by other therapists resulted in positive effects
[51, 52]. If adverse effects are reported, it might not be
clear how these are attributed. Although evidence from
RCTs provides the strongest conclusions [20], uncer-
tainty concerning the causality of adverse effects might
remain; are they truly treatment effects, or actually ther-
apist effects, or caused by other factors such as changes
in the life of the patients? Hence, it is not likely that we
will be able to answer these important causality ques-
tions by means of the present meta-analysis although we
will at least assess if studies consider possible therapist
effects in the data analyses of outcomes and negative ef-
fects. Even though causality considerations are import-
ant, it has been argued that at the recent stage of
research, “the question of causality lacks pragmatic sali-
ence” (p. 23) [6]. Due to unresolved methodological diffi-
culties, it seems reasonable to keep causality in mind
while focusing on our review primarily on outcome
prognosis as both a realistic and relevant goal [6].
It has been shown that the frequency of adverse events
depends on the methods used for assessment. This may
cause heterogeneity in the comparison between studies
[53–55]. In order to face this problem, we will develop a
checklist and ask the authors from eligible primary studies
about any patient reports on adverse events that were not
mentioned in their publications. As we will code treat-
ment non-response and deterioration as defined by the
authors of the primary studies, these definitions might dif-
fer from each other. Implementing the Reliable Change
Index as a common measure will help minimising these
possible variations. This meta-analysis is facing the same
problems as any of its kind; difficulties performing all
planned analysis may arise dependent on the number of
included comparisons and adequate power.
We are aware that the preselection of studies with regard
to RCTs might induce bias due to dropout before the be-
ginning of treatment or end of treatment. However, we will
thoroughly assess the negative effects of randomisation as
well, e.g. reasons for non-randomisation, if reported. Be-
cause of few participants and short duration of trials, ad-
verse events which occur seldom or delayed can be
overlooked in RCTs. On the other hand, non-randomised
studies bear other disadvantages, e.g. being more vulnerable
to biases [29] and underestimating the absolute risk of
harm [56]. Since “randomized controlled trials are the only
possibility to obtain causal clinical evidence regarding AEs
[adverse events] and SAEs [serious adverse events] and
therefore constitute a unique and important source for pa-
tient safety information” (p. 106) [17], the advantages out-
weigh the disadvantages for our purpose.
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